Jiang J, Srivastava S, Zhang J. Starve cancer cells of glutamine: break the spell or make a hungry monster? Cancers. 2019;11(6):804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masisi BK, El Ansari R, Alfarsi L, Rakha EA, Green AR, Craze ML. The role of glutaminase in cancer. Histopathology. 2020;76(4):498–508.

Article  PubMed  Google Scholar 

Mates JM, Campos-Sandoval JA, Santos-Jimenez JL, Marquez J. Dysregulation of glutaminase and glutamine synthetase in cancer. Cancer Lett. 2019;467:29–39.

Article  CAS  PubMed  Google Scholar 

Lampa M, Arlt H, He T, Ospina B, Reeves J, Zhang B, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS ONE. 2017;12(9): e0185092.

Article  PubMed  PubMed Central  Google Scholar 

Singleton DC, Dechaume AL, Murray PM, Katt WP, Baguley BC, Leung EY. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer. 2020;20(1):470.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890–901.

Article  CAS  PubMed  Google Scholar 

Kalinsky K, Harding JJ, DeMichele A, Infante JR, Gogineni K, Owaonikoko TK, et al. Abstract PD3–13: phase I study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer. Cancer Res. 2018;78(4_supplement):PD3-13.

Article  Google Scholar 

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163(2):506–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121(7):2750–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688–98.

Article  CAS  PubMed  Google Scholar 

Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23.

Article  CAS  PubMed  Google Scholar 

Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: the next frontier in precision oncology. Oncotarget. 2017;8(63):106167–8.

Article  PubMed  PubMed Central  Google Scholar 

Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):140100.

Article  PubMed  Google Scholar 

Fu A, Yu Z, Song Y, Zhang E. Silencing of glutaminase 1 resensitizes Taxol-resistant breast cancer cells to Taxol. Mol Med Rep. 2015;11(6):4727–33.

Article  CAS  PubMed  Google Scholar 

NCT03057600. Study of CB-839 in combination with paclitaxel in patients of African ancestry and Non-African ancestry with advanced TNBC. Available online: https://clinicaltrials.gov/ct2/show/NCT03057600. Accessed 15 Dec 2022.

Craze ML, Cheung H, Jewa N, Coimbra NDM, Soria D, El-Ansari R, et al. MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. Br J Cancer. 2018;118(2):258–65. https://doi.org/10.1038/bjc.2017.387.

Article  CAS  PubMed  Google Scholar 

Cacace A, Sboarina M, Vazeille T, Sonveaux P. Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism. Oncogene. 2017;36(15):2074–84. https://doi.org/10.1038/onc.2016.364.

Article  CAS  PubMed  Google Scholar 

Mates JM, Campos-Sandoval JA, de Los Santos-Jimenez J, Marquez J. Glutaminases regulate glutathione and oxidative stress in cancer. Arch Toxicol. 2020.

Wang T, Cai B, Ding M, Su Z, Liu Y, Shen L. c-Myc overexpression promotes oral cancer cell proliferation and migration by enhancing glutaminase and glutamine synthetase activity. Am J Med Sci. 2019;358(3):235–42.

Article  PubMed  Google Scholar